A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is quite modest this time around. We plan to catch up on some reading, hang with our short person, and take a few naps. And what about you? Given the to-do over taxes in Washington, you could run some numbers and see how your fortunes play out — will you be a winner or loser? You could also calculate how your cable bill might change if certain regulators dispense with a certain rule. Or you could simply shrug your shoulders and take a long walk in the park. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Amazon (AMZN) has held preliminary talks with generic drug makers about its potential entry into the pharmacy business, according to CNBC, citing an investor note by Leerink analysts. The conversations, with Mylan and the Sandoz unit of Novartis (NVS), have been described as high level, but the nature of Amazon’s plans is not yet clear. One of the people said the talks are about Amazon taking a role in drug purchasing.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.